Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.

With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Current health news highlights include Apollo Hospitals' AI investments to alleviate staff workload, Dr. Mehmet Oz's Medicare ...

Health-care companies fell, but not by as much as the broad market, as traders sought out defensive sectors. Drugmaker Mallinckrodt struck a deal to buy rival Endo, one of the drug makers driven into ...

The voluntary survey includes questions on how productive their office is, how much they use AI, and whether they're ...

European stocks rebounded yesterday after four days of declines as Ukraine accepted a ceasefire proposal brokered ...

Stocks entered a correction on Thursday as the S&P 500 index fell 10% from its recent peak after President Donald Trump ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) ...